11:57 AM EST - Nuvo Research Inc. : announced that its U.S. marketing partner, Mallinckrodt Inc., a Covidien company has announced that they intend to pursue the Supplementary New Drug Application (sNDA) regulatory approval pathway for PENNSAID(®) Viscous Solution instead of using the 505(b)(2) pathway for new drug approval, as previously planned. Nuvo Research Inc.
shares T.NRI are trading even at $0.08.
